Abstract
There has been an explosion of our knowledge in cytokine biology in the last decade. Such knowledge is being quickly translated into the identification of etiologies and improved prophylaxis and therapy of disease. While cytokines have the potential to be used as therapeutics or immune adjuvants for certain diseases, they may also be culprits as therapeutic targets in other diseases. This review article serves as an introduction to the other five articles in this thematic issue each of which has a specific focus on the frontier of cytokine therapeutic biology. This review contains sections dealing with general cytokine properties, cytokine classifications, human conditions caused by cytokine under-expression and over-expression, Th1 and Th2 paradigm, cytokine therapy for acute/chronic inflammatory conditions, cytokine therapy for infectious diseases, and cytokine therapy for cancer.
Keywords: Cytokines, Therapeutics Agnets, Prophylaxis, Th1, Th2, paradigm, therapy, Inflammatory, Infectious diseases, Recombinant, Immune, prophylactic vaccines, autoimmune, cancer, transgene, receptors, Chronic, Wound Healing, GM CSF, Fibrotic, Bronchial Asthma, Rheumatoid Arthritis
Current Pharmaceutical Design
Title: Consideration of Cytokines as Therapeutics Agents or Targets
Volume: 6 Issue: 6
Author(s): Zhou Xing and Jun Wang
Affiliation:
Keywords: Cytokines, Therapeutics Agnets, Prophylaxis, Th1, Th2, paradigm, therapy, Inflammatory, Infectious diseases, Recombinant, Immune, prophylactic vaccines, autoimmune, cancer, transgene, receptors, Chronic, Wound Healing, GM CSF, Fibrotic, Bronchial Asthma, Rheumatoid Arthritis
Abstract: There has been an explosion of our knowledge in cytokine biology in the last decade. Such knowledge is being quickly translated into the identification of etiologies and improved prophylaxis and therapy of disease. While cytokines have the potential to be used as therapeutics or immune adjuvants for certain diseases, they may also be culprits as therapeutic targets in other diseases. This review article serves as an introduction to the other five articles in this thematic issue each of which has a specific focus on the frontier of cytokine therapeutic biology. This review contains sections dealing with general cytokine properties, cytokine classifications, human conditions caused by cytokine under-expression and over-expression, Th1 and Th2 paradigm, cytokine therapy for acute/chronic inflammatory conditions, cytokine therapy for infectious diseases, and cytokine therapy for cancer.
Export Options
About this article
Cite this article as:
Xing Zhou and Wang Jun, Consideration of Cytokines as Therapeutics Agents or Targets, Current Pharmaceutical Design 2000; 6 (6) . https://dx.doi.org/10.2174/1381612003400623
DOI https://dx.doi.org/10.2174/1381612003400623 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review
Current Medicinal Chemistry Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Allergic Inflammation and the Oral Mucosa
Recent Patents on Inflammation & Allergy Drug Discovery Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review
Current Pharmaceutical Design Aminopeptidase N (APN/CD13) as a Target for Anti-Cancer Agent Design
Current Medicinal Chemistry An Overview of Antiretroviral Agents for Treating HIV Infection in Paediatric Population
Current Medicinal Chemistry Objective Biomarkers or Symptom Scores for the Classification of Fibromyalgia Syndrome?
Current Rheumatology Reviews Nucleic Acids Modulate Autoimmunity Through Nucleic-Acid-Specific Toll-Like Receptors
Current Medicinal Chemistry Cell Biology and Lipoproteins in Atherosclerosis
Current Molecular Medicine Meet Our Editorial Board Member
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Pleuroparenchymal Fibroelastosis: Its Clinical Characteristics
Current Respiratory Medicine Reviews Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
Current Pharmaceutical Design Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology